Resin cleavage: difference between revisions
Diff·revision 15 → 16·22:26, 11 Jun 2025
Difference between revision 15 and revision 16 of Resin cleavage. 6 lines changed; the page grew by 725 bytes.
| Revision 15 — 18:42, 10 May 2025 Chromatokid (talk) rm the blanket claim that excursions are harmless 3,304 bytes +27 | Revision 16 — 22:26, 11 Jun 2025 SPPS_Sorrel (talk) expand §Cocktails and scavengers 4,029 bytes +725 | ||
|---|---|---|---|
| 27 | Residual ether is a [[Residual solvent|residual solvent]] of Class 3, and residual trifluoroacetic acid becomes the [[Trifluoroacetate counterion|counterion]] of the isolated solid.{{r|usp1503}} | 27 | Residual ether is a [[Residual solvent|residual solvent]] of Class 3, and residual trifluoroacetic acid becomes the [[Trifluoroacetate counterion|counterion]] of the isolated solid.{{r|usp1503}} |
| 28 | 28 | ||
| + | 29 | == Signatures in the product == | |
| + | 30 | Cleavage-derived impurities are chemically distinctive. Alkylated residues carry a characteristic mass addition, detectable by [[Mass spectrometry|mass spectrometry]]; oxidised methionine adds 16 Da; incompletely deprotected species carry the mass of the retained group.{{r|aebersold2003}} | |
| + | 31 | ||
| + | 32 | Because these masses are large and distinctive, cleavage-derived impurities are among the easier ones to identify when a full mass spectrum is available — in contrast to deletion sequences and isomers, which need chromatographic resolution.{{r|usp1503}} | |
| + | 33 | ||
| 29 | == References == | 34 | == References == |
| 30 | {{reflist}} | 35 | {{reflist}} |
| 31 | <ref name="behrendt2016">Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." ''Journal of Peptide Science'' 22(1):4–27 (2016). PMID 26785684.</ref> | 36 | <ref name="behrendt2016">Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." ''Journal of Peptide Science'' 22(1):4–27 (2016). PMID 26785684.</ref> |
| 32 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 37 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 38 | <ref name="aebersold2003">Aebersold R, Mann M. "Mass spectrometry-based proteomics." ''Nature'' 422(6928):198–207 (2003). PMID 12634793.</ref> | |
| 33 | 39 | ||
| 34 | == See also == | 40 | == See also == |